#AS­CO21: Adap­ti­m­mune gives first glimpse at piv­otal da­ta for what they hope will be first ap­proved TCR

Six years af­ter Adap­ti­m­mune hauled what at the time was one of biotech’s largest-ever IPOs, CEO Adri­an Raw­cliffe thinks they’re fi­nal­ly on track to get the first TCR ther­a­py over the fin­ish line.

Adap­ti­m­mune re­leased new da­ta Wednes­day show­ing their TCR ther­a­py, known as afa­mi-cel, shrunk the tu­mors of 13 of the 33 evalu­able sec­ond-line sar­co­ma pa­tients, in­clud­ing two pa­tients whose tu­mors melt­ed en­tire­ly. That was good for a 39% ob­jec­tive re­sponse rate — which Raw­cliffe char­ac­ter­ized as a ma­jor ad­vance. He con­trast­ed it with the hand­ful of oth­er treat­ments avail­able for these pa­tients, such as Votri­ent, a chemother­a­py with a re­sponse rate in the sin­gle dig­its or low teens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER